Evidence map›Paper›PMID 35698080›Full record

SynthesisOrphanet journal of rare diseases2022

A lack of race and ethnicity data in the treatment of hereditary hemorrhagic telangiectasia: a systematic review of intravenous bevacizumab efficacy.

Panagis Galiatsatos, Cheri Wilson, Jaime O'Brien, Anna J Gong, Dylan Angiolillo, James Johnson, Carlie Myers, Sara Strout, Stephen Mathai, Gina Robinson and 2 more

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Orphanet journal of rare diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Psoralen: a narrative review of current and future therapeutic uses.Journal of cancer research and clinical oncology · 2024
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Panagis GaliatsatosDivision of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA. panagis@jhmi.edu.ORCID 0000-0001-8309-0985
Cheri WilsonOffice of Diversity, Inclusion, and Health Equity, Baltimore, MD, USA.
Jaime O'BrienAlbert Gnaegi Center for Health Care Ethics, Saint Louis University, Saint Louis, MO, USA.
Anna J GongThe Center of Clinical Excellence for Hereditary Hemorrhagic Telangiectasias at the Johns Hopkins Hospital, Baltimore, MD, USA.
Dylan AngiolilloMedicine for the Greater Good, Johns Hopkins School of Medicine, 4940 Eastern Avenue, 4th Floor, Asthma and Allergy Building, Baltimore, MD, 21224, USA.
James JohnsonMedicine for the Greater Good, Johns Hopkins School of Medicine, 4940 Eastern Avenue, 4th Floor, Asthma and Allergy Building, Baltimore, MD, 21224, USA.
Carlie MyersDivision of Anesthesiology and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Sara StroutDepartment of Pharmacy, Johns Hopkins Hospital, Baltimore, MD, USA.
Stephen MathaiDivision of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Gina RobinsonThe Center of Clinical Excellence for Hereditary Hemorrhagic Telangiectasias at the Johns Hopkins Hospital, Baltimore, MD, USA.
Nicholas R RowanThe Center of Clinical Excellence for Hereditary Hemorrhagic Telangiectasias at the Johns Hopkins Hospital, Baltimore, MD, USA.
Clifford R WeissThe Center of Clinical Excellence for Hereditary Hemorrhagic Telangiectasias at the Johns Hopkins Hospital, Baltimore, MD, USA.
Johns Hopkins Hospital · USJohns Hopkins University · USOffice of Diversity and Inclusion · USSaint Louis University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFor extreme hereditary hemorrhagic telangiectasia (HHT) disease, treatments such as intravenous bevacizumab are often utilized. However, whether its efficacy is similar across diverse races and ethnicities is unclear.

methodsIn this systematic review, we performed a search for English-language articles identified through PubMed, Embase, and Scopus databases whose research occurred in the United States (US). Search terms related to HHT, epistaxis, and intravenous bevacizumab. We searched specifically for the intervention of intravenous bevacizumab because the term serves as a suitable surrogate to convey a patient who has both a diagnosis of HHT and established care. We focused on number of patients recruited in intravenous bevacizumab trials who were identified by race or ethnicity.

resultsOur search identified 79 studies, of which four were conducted in the US. These four were selected for our systematic review. In these studies, 58 total patients were evaluated (ranging from 5 to 34 participants), whereby, information on age and gender were included. However, none of the US-based studies shared race or ethnicity data.

conclusionInability to find studies regarding intravenous bevacizumab use in patients with HHT in which race and ethnicity are reported limits our ability to understand the therapy's efficacy in specific populations. Without emphasis on race and ethnicity in such trials, showing the potential of HHT-related diversity in individuals with this disease may reaffirm implicit bias around HHT diagnosis and treatment. Future work on HHT should emphasize sociodemographic data collection and reporting in an effort to understand this disease in diverse populations.

Indexed as

Telangiectasia, Hereditary HemorrhagicBevacizumabEpistaxisEthnicityHumansInfusions, IntravenousBevacizumabBevacizumabHealth equityHereditary hemorrhagic telangiectasiaRace

Identifiers

PMID35698080
PMCPMC9195340
OpenAlexW4282576053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.